Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron COVID-19 Antibody Poised To Add Prevention Claim, Sub-Q Formula

Executive Summary

The company is requesting FDA expand the antibody cocktail to include a COVID prevention claim with a lower 1,200mg dose and a subcutaneously administered formula.

You may also be interested in...



AZ’s STORM CHASER Falls Short On Ambitious COVID Symptom Goal

AstraZeneca had wanted to outperform Regeneron and Lilly in post-exposure prevention, but will now hope for more durable protection from its long-acting antibody.

GSK/Vir’s Covid Antibody Gains EU Clearance, But Demand May Have Peaked

The green light for the COVID-19 antibody therapy is welcome news for the partners, but rising vaccination rates plus three other competitors in Europe will limit revenues.

Coronavirus Update: Storage Boost For Pfizer/BioNTech, More Positive Data For Regeneron Antibody Cocktail

The approved fridge storage time for Pfizer and BioNTech's Comirnaty has been extended to a month, Regeneron's scores with low-dose REGEN-COV, an early win for GSK and CureVac's next-generation mRNA vaccine and more orders of the AstraZeneca vaccine benefits Oxford Biomedica's bank balance.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel